Skip to main content
SpringerLink
Log in

Mucosal Healing in Ulcerative Colitis

  • Chapter
  • First Online:
Advances in Endoscopy in Inflammatory Bowel Disease

  • 1383 Accesses

Abstract

Nowadays, the relevance of the endoscopic activity of ulcerative colitis (UC) has been translated into the new concept of “mucosal healing (MH)” as the therapeutic goal to achieve, because considerable scientific evidence indicated the favorable prognostic value of a healed mucosa in clinical outcome of UC. In this regard, MH assessed by endoscopy seems almost like the “gold standard” for evaluating UC activity. On the other hand, we should recognize that there were no prospectively validated endoscopic scoring systems of UC activity in previous clinical trials. In the future, development of new endoscopic scoring systems, which are prospectively validated, will standardize the definition of MH. In addition, recent interest on mucosal healing skews toward not only endoscopic remission but also histological improvement (so-called histological MH). To be precise, histological MH can be an ideal goal for treatment of UC. However, it seems to be more difficult to decide the exact definition of histological MH than that of endoscopic MH. New endoscopic techniques, “confocal endomicroscopy in vivo”, might be promising modalities in the assessment of MH. We should await data concerning the real-time evaluation of MH in UC patients by confocal endomicroscopy. There are many issues to be addressed with regard to standardization of MH, therefore, “The road to justification of MH in the treatment of UC has just started ”.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;15:796–800.

    Article  PubMed  Google Scholar 

  2. lacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4:129–43.

    Article  Google Scholar 

  3. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966;11:847–57.

    Article  CAS  PubMed  Google Scholar 

  4. Courtney MG, Nunes DP, Bergin CF, et al. Colonoscopic appearance in remission predicts relapse of ulcerative colitis. Gastroenterology. 1991;100:A205.

    Google Scholar 

  5. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20.

    Article  CAS  PubMed  Google Scholar 

  6. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–35.

    Article  CAS  PubMed  Google Scholar 

  7. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Baron JH, Connell AM, Lennard-jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–7.

    Article  CAS  PubMed  Google Scholar 

  10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–9.

    Article  CAS  PubMed  Google Scholar 

  11. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.

    Article  CAS  PubMed  Google Scholar 

  12. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499–507.

    Article  CAS  PubMed  Google Scholar 

  14. D’Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006;24:1087–97.

    Article  PubMed  Google Scholar 

  15. Rogler G, Vavricka S, Schoepfer A, et al. Mucosal healing and deep remission: what does it mean? World J Gastroenterol. 2013;19:7552–60.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Feagan BG, Sandborn WJ, D’Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013;145:149.e2–57.e2.

    Article  Google Scholar 

  17. Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987–95.

    Article  PubMed  Google Scholar 

  18. Samuel S, Bruining DH, Loftus EV, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013;11:49.e1–54.e1.

    Article  Google Scholar 

  19. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.

    Article  PubMed  Google Scholar 

  20. Korelitz BI, Sommers SC. Response to drug therapy in Crohn’s disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol. 1984;6:123–7.

    Article  CAS  PubMed  Google Scholar 

  21. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107:1684–92.

    Article  PubMed  Google Scholar 

  22. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929.e2–34.e2.

    Google Scholar 

  23. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  CAS  PubMed  Google Scholar 

  24. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.

    Article  CAS  PubMed  Google Scholar 

  25. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16:1905–11.

    Article  PubMed  Google Scholar 

  26. Ardizzone S, Cassinotti A, Duca P, et al.. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483.e3–9.e3.

    Google Scholar 

  27. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.

    Article  PubMed  Google Scholar 

  28. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–40.

    Google Scholar 

  29. Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;32:516–26.

    Article  Google Scholar 

  30. Eden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.

    Article  Google Scholar 

  31. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.

    Article  PubMed  Google Scholar 

  32. Actis GC, Pellicano R, David E, et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm Allergy Drug Targets. 2010;9:6–9.

    Article  CAS  PubMed  Google Scholar 

  33. Korelitz BL, Sultan K, Kothari M, et al. Histological healing favors lower risks of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol. 2014;20:4980–6.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Watanabe O, Ando T, Maeda O, et al. Confocal endomicroscopy in patients with ulcerative colitis. J Gastroenterol Hepatol. 2008;23(Suppl 2):S286–90.

    Article  PubMed  Google Scholar 

  35. Li CQ, Xie XJ, Yu T, et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol. 2010;105:1391–6.

    Article  PubMed  Google Scholar 

  36. Moussata D, Goetz M, Watson AJ, et al. Confocal laser endomicroscopy for the in vivo identification, localization and quantification of tissue based basteria in patients with different types of colitis. Gastrointest Endosc. 2009;69:131.

    Google Scholar 

  37. Neumann H, Fuchs FS, Vieth M, et al. Review article: in vivo imaging by endocytoscopy. Aliment Pharmacol Ther. 2011;33:1183–93.

    Google Scholar 

  38. Minami H, Inoue H, Yokoyama A, et al. Recent advancement of observing living cells in the esophagus using CM double staining: endocytoscopic atypia classification. Dis Esophagus. 2012;25:235–41.

    Google Scholar 

  39. Bessho R, Kanai T, Hosoe N, et al. Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis. J Gastroenterol. 2011;46:1197–202.

    Article  PubMed  Google Scholar 

  40. Neumann H, Vieth M, Neurath MF, et al. Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD: a pilot study. Inflamm Bowel Dis. 2013;19:356–62.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Sapporo Medical Univeristy School of Medicine, S-1, W-16, Chuo-Ku, Sapporo, Hokkaido, 060-8543, Japan

    Hiroshi Nakase, Tomoya Iida, Kentaro Kawakami & Daisuke Hirayama

Authors
  1. Hiroshi Nakase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoya Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kentaro Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Hirayama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Nakase .

Editor information

Editors and Affiliations

  1. Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Insitiute Hospital, Minato-ku, Tokyo, Japan

    Toshifumi Hibi

  2. The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan

    Tadakazu Hisamatsu

  3. Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Insitiute Hospital, Minato-ku, Tokyo, Japan

    Taku Kobayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Japan

About this chapter

Cite this chapter

Nakase, H., Iida, T., Kawakami, K., Hirayama, D. (2018). Mucosal Healing in Ulcerative Colitis. In: Hibi, T., Hisamatsu, T., Kobayashi, T. (eds) Advances in Endoscopy in Inflammatory Bowel Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56018-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-56018-0_18

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-56016-6

  • Online ISBN: 978-4-431-56018-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation